Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03614260 · ClinicalTrials.gov registry record · NA
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension
A NA study of Hypertension and Cardiovascular Diseases, sponsored by ReCor Medical.
- Active
- Registry status
- NA
- Development phase
- 225
- Enrollment target
- 20
- Study locations
NCT03614260: Active NA study of Hypertension and Cardiovascular Diseases, sponsored by ReCor Medical.
NCT03614260 is a NA study of Hypertension and Cardiovascular Diseases that is active but no longer recruiting, run by ReCor Medical. The registered enrollment target is 225 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03614260, a NA study of Hypertension and Cardiovascular Diseases, is active but no longer recruiting, sponsored by ReCor Medical.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 225 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of the RADIANCE II Pivotal study is to demonstrate the effectiveness and safety of the Paradise System in subjects with Stage 2 hypertension on 0-2 medications at the time of consent. Prior to randomization, subjects will be hypertensive in the absence of hypertension medication.
Conditions Studied
Interventions
- DEVICE Paradise Renal Denervation System
- PROCEDURE Renal Angiogram
Study Locations (20)
Connecticut
- Bridgeport Hospital - Bridgeport
- Stamford Hospital - Stamford
Illinois
- Northwestern University - Chicago
- Southern Illinois University - Springfield
New Jersey
- Deborah Heart & Lung Center - Browns Mills
- Hackensack University - Hackensack
New York
- Columbia University Medical Center/NYPH - New York
- Northwell Health Inc. - New York
Alabama
- Cardiology PC - Birmingham
California
- Cedars Sinai Medical Center - Los Angeles
District of Columbia
- MedStar Washington - Washington D.C.
Florida
- The Cardiac and Vascular Institute - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2018-12-14 |
| Est. Completion | 2027-07 |
| Phase | NA |
What the registry record for NCT03614260 still lists
NCT03614260 is an interventional study that assigns participants to a tested intervention. The registered 225 participants enrollment target is mid-sized for trials with a published cap, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (94% lower).
The record links to 3 conditions, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Paradise Renal Denervation System is the first listed.
NCT03614260 names 20 study sites across 16 states, led by Connecticut, Illinois, New Jersey.
Frequently Asked Questions
What is clinical trial NCT03614260 about?
NCT03614260 is a clinical study titled "The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension". The objective of the RADIANCE II Pivotal study is to demonstrate the effectiveness and safety of the Paradise System in subjects with Stage 2 hypertension on 0-2 medications at the time of consent. Prior to randomization, subjects will be hypertensive in the absence of hypertension medication.
What is the current status of trial NCT03614260?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 225 participants. The study started on 2018-12-14. Estimated completion is 2027-07.
What conditions does trial NCT03614260 study?
This clinical trial studies the following conditions: Hypertension, Cardiovascular Diseases, Vascular Diseases.
What interventions are being tested in trial NCT03614260?
The interventions under investigation include: Paradise Renal Denervation System (DEVICE), Renal Angiogram (PROCEDURE).
Who is sponsoring clinical trial NCT03614260?
This trial is sponsored by ReCor Medical, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03614260 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03614260's enrollment target sits among peer trials
225 204th of 470 higher than 266 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
-
How a Mediterranean Diet With Potatoes Impacts Heart and Metabolic Health in Adults With Pre-Diabetes
RECRUITING · NA
-
Conical Forearm and Cylindrical Upper Arm Non-Invasive Blood Pressure (NIBP) Measurements in Pregnant Patients
RECRUITING · NA
-
Comparing Healthcare Visit Recording and Open Notes to Improve Chronic iLlness Care Experience in Older Adults
RECRUITING · NA
-
Early Time-Restricted Eating in Older Adults With Hypertension
RECRUITING · NA
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03955445 · 225 participants · Phase 3
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
- NCT04054310 · 225 participants · NA
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- NCT04480554 · 225 participants · Phase 2
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
- NCT04888104 · 225 participants
Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI